Background: Guidelines suggest that patients on continuous antiretroviral therapy for >4 months with current viral load (VL)>1,000 copies/ml should be tested for resistance. There are limited data showing the frequency of resistance testing in routine clinical practice following these recommendations. Methods: In EuroSIDA, virological failure (VF) was defined as confirmed VL>1,000 copies/ml after ≥4 months continuous use of any antiretroviral in a ≥3-drug regimen started during or after 2002. We assessed whether a resistance test was performed around VF (from 4 months before to 1 year after VF) and used logistic regression analysis to assess factors associated with having a resistance test. Conclusions: This analysis suggests a delay in genotypic testing after VF that seems longer than expected given current treatment guidelines. This delay is highly variable across Europe.
Potent combination antiretroviral therapy (cART) has significantly reduced HIV-related morbidity and mortality in the developed world [1] , but responses to therapy may diminish over time and lead to virological failure (VF). Treatment guidelines recommend starting a new regimen containing ≥2 active antiretrovirals (ARVs) [2, 3] following VF, where resistance tests in combination with knowledge of the patient's treatment history should be used to determine which ARVs are likely to be active.
HIV resistance testing guidelines have been regularly updated since their introduction in 1998 [4] [5] [6] . It is uncertain how these guidelines are followed in practice across Europe and whether resistance tests are conducted comprehensively and promptly following VF. Because mutations may predict long-term virological and clinical outcomes [7] [8] [9] [10] , appropriate use of resistance testing following VF is crucial. In this study, data from EuroSIDA are used to assess the probability of having a genotypic resistance test at or 
Methods
We included patients who started a new cART regimen (that is, ≥3 drugs from ≥2 drug classes) at/after 2002 (not necessarily their first regimen) and had VF while still on cART. A patient was considered to have VF and an indication for a resistance test if they had confirmed viral load (VL)>1,000 copies/ml (confirmed at the subsequent visit) after ≥4 months continuous use of any drug in the regimen. This included both patients with continuous VL>1,000 copies/ml in the 4 months after starting cART, and those with VL rebound to >1,000 copies/ml ≥4 months after starting cART. We included the first VF at/after 2002 in each patient and only included one episode per patient.
Patients were followed-up in EuroSIDA [11] . EuroSIDA is an ongoing, longitudinal study that currently includes 16,599 HIV-infected patients. Data on CD4 + T-cell counts and VL levels measured since the last follow-up visit and dates of starting and stopping each ARV were collected at each follow-up visit. Data collection on the utilization and findings of resistance tests has been standardized since January 2002; therefore, our analysis explores resistance tests performed on-site at/after this date. Sites that reported at least one resistance test were included in these analyses. Argentina was excluded in order to study regional variations across Europe. Data are presented according to predefined zones of Europe, as used previously (Table 1 ) [12] .
We investigated the characteristics of patients at VF and explored the proportion of patients with a resistance test from 4 months prior to and up to 1 year post-VF. Baseline covariates and time-updated factors were explored using logistic regression analysis. Statistical analyses were performed using STATA software (version 10.1; StataCorp., College Station, TX, USA).
Results
There were Overall, we observed VF in 1,090 (15.1%) patients, where 552 (50.6%) had previously experienced VL<500 copies/ml on their regimen. Patients had used their regimens for a median (range) 8.1 months (4.0 months to 6.3 years) at VF; 928 (85.1%) patients were followed for ≥1 year following VF. The population was primarily male (74.7%), White (88.0%) and had cARTexperience prior to 2002 (79.8%; Table 2 ). There were 393 (36.1%) patients with a pre-VF resistance test (that is, >4 months preceding VF) and 395 (36.2%; 95% CI 33.4-39.1) with a resistance test from 4 months prior to and up to 1 year following VF. There were 287/395 (72.7%) patients with a resistance test and 369/695 (53.1%) of those without a resistance test who changed ARVs in the year following VF.
Overall, the proportions of patients with a resistance test from 4 months before the date of VF to 1 year afterwards varied according to different risk factors ( Figure 1A ). Figure 1B ).
Discussion
In our study of individuals with VF, the probability of a resistance being performed around the time of the VF or within 1 year afterwards was 36.2%, which is consistent with results from the UK CHIC study [13] . Some of the reasons why clinicians may not perform resistance tests following VF could be: if a patient has perceived poor adherence and is unlikely to show any mutations; if new drugs can be chosen in the absence of a resistance test or if a patient is likely to show extensive mutations and will have no drugs to switch to.
Of the patients without a resistance test, 47% did not change medication in the year following VF, illustrating that known non-compliance, unawareness of VL levels, unwillingness to change therapy, or unavailability of alternative options could explain why resistance tests were not performed. In this study, data come from clinical forms in which it is indicated whether a resistance test was done on-site; because we do not have genotypes for all patients studied here, we are unable to estimate treatment options at VF.
Other explanations for the low rates of resistance testing are variability in how the clinicians interpret guidelines and clinician inexperience. In addition, although we try to ensure comprehensive collection of data, we cannot rule out the possibility that data on resistance testing is not always complete.
Lack of available drugs and limited access to genotyping is likely to explain the low testing rates we saw in Eastern Europe [12] . Considering the costs of resistance tests in combination with the specialized equipment/personnel needed and the fact that only 22% of adults in need of cART in Eastern Europe are receiving it [14] , treatment expansion is likely to be more of a priority than resistance testing in Eastern Europe [15, 16] . Treatment failure is common in Eastern Europe [12] and because increasing levels of resistance have been noted there [17, 18] it is crucial to test for resistance before changing treatment.
Between 2005 and 2007, there was an increase in the number of drug possibilities (that is, with the introduction of darunavir/ritonavir, etravirine, maraviroc and raltegravir) and because these drugs are likely to be considered active irrespective of mutations that are present, this may have resulted in the decrease in resistance testing we see in later years.
Having a previous resistance test was a strong predictor of having one at the time of VF. This observation may suggest that availability of tests plays a significant role, or that patients who underwent timely testing may be perceived to be at greater risk of resistance It is difficult to control for all confounders in the analysis because some are not known and others are not available. For example, there are no data on local availability of resistance tests or on regional variations on the implementation of guidelines. Furthermore, there are no data on the level of experience/ expertise of providers by region.
In summary, these results indicate a relatively slow rate of resistance testing following VF. In the modern era, with the approval of new ARVs that are less compromised by resistance mutations, delays in testing may be less of an issue. However, it is likely to become an issue again once these new ARVs are used widely and for prolonged periods of time. In our analysis there was a marked lower utilization of resistance tests in Central East and Eastern Europe compared with Northern Europe, suggesting that different resistance testing benchmarks have been utilized across Europe. There is a need to better understand why geographical differences exist in resistance testing, not only within areas of Europe with less access to genotyping, but also between regions that are likely to have similarly good access to testing.
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